The Influence of Peripheral Androgen Conversion at Women Adult Acne

Sponsor

Marco Alexandre Dias da Rocha (Other)

Overall Status

Unknown status

CT.gov ID

NCT01850095

Collaborator

Fleury (Other), Associacao Fundo de Incentivo a Psicofarmcologia (Other), Bayer (Industry)

Enrollment

Location

Arms

Duration (Months)

1.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Acne vulgaris is a chronic inflammatory disease that affects the pilosebaceous unit. Recent studies have demonstrated an increase number of acne cases in adult women. These cases are predominantly normoandrogenic and have some clinical differences when compared with the most common group, the adolescent. The local glandular metabolism converts some hormonal precursors to more active substances that increase the sebum production, leaving these areas more prone to increase the colonization to Propionibacterium Acnes (P. Acnes). Toll-like receptor 2, expressed by inflammatory cells play a crucial role in the innate immune response to this bacterium. Previous studies confirm that exist a reduced expression of CD1d by keratinocytes in acne lesion, what can be interpreted as a low antigen-present function. The influence of hormonal alteration in the sebaceous glands could modulate the expressions of TLR-2 and CD1d explaining the persistence of lesions in adult women. The change to more estrogenic metabolism, with use of specific contraceptive pills could normalize this immune-mediated inflammatory process.

Objective

To analyze how the peripheral androgen conversion can influence the toll-like receptor 2 and CD1d expression in women with inflammatory acne before and after 6 months of oral contraceptives with anti-androgen activity.

Condition or Disease	Intervention/Treatment	Phase
Acne Quality of Life	Drug: treatment azelaic acid (azelan) Drug: dorspirenone/ethynil estradiol	N/A

Study Design

Study Type:

Interventional

Anticipated Enrollment :

60 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Single (Outcomes Assessor)

Primary Purpose:

Diagnostic

Official Title:

The Influence of Peripheral Androgen Conversion at Toll-like Receptors-2 and CD1d Expressions in Human Keratinocytes as Well as Their Modulation After 6 Months Treatment With Oral Contraceptive.

Study Start Date :

Mar 1, 2012

Anticipated Primary Completion Date :

Jun 1, 2013

Anticipated Study Completion Date :

Jan 1, 2015

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: treatment 1 topical acid azelaic, used 2 times a day for 6 months	Drug: treatment azelaic acid (azelan) treatment for 6 months Other Names: azelaic acid (azelan)
Active Comparator: treatment 2 contraceptive with drospirenone/ethinyl estradiol used for 6 months	Drug: dorspirenone/ethynil estradiol Other Names: (yaz)
No Intervention: control control group ( only take biopsies and blood samples )

Arm

Intervention/Treatment

Active Comparator: treatment 1

topical acid azelaic, used 2 times a day for 6 months

Drug: treatment azelaic acid (azelan)

treatment for 6 months

Other Names:

azelaic acid (azelan)

Active Comparator: treatment 2

contraceptive with drospirenone/ethinyl estradiol used for 6 months

Drug: dorspirenone/ethynil estradiol

Other Names:

(yaz)

No Intervention: control

control group ( only take biopsies and blood samples )

Outcome Measures

Primary Outcome Measures

Clinical evaluation of the treatment group [6 months]
by the researcher: by counting the inflammatory lesions. by the research subjects: the general appearance of skin at the time of study entry and after the treatment. Will be used a 4-point scale: 0 = no acne, 1 = mild acne, moderate acne, and 2 = 4 = severe acne.

Secondary Outcome Measures

Photographic study of the treatment group [6 months]
This evaluation will be performed by two independent dermatologists, the degree of change in the intensity of acne, comparing the pre and post treatment photos through a 5-point scale: -2 = much worse, -1 = worse, 0 = unchanged; +1 = better, +2 = much better.

Other Outcome Measures

Application of the questionnaire index of quality of life in Acne [6 months]
AcneQol (Girman et al, 1996, Martin et al, 2001, Fehnel et al, 2003),
Immunohistochemical analysis with quantitative digital blind: [6 months]
For immunohistochemistry will be used the following markers: a polyclonal rabbit anti-TLR2 (ABBIOTEC 251,110) Biogen, Brazil. mouse monoclonal anti-CD1d, clone NOR3.2 (Genway 20-272-1903). Biogen, Brazil. Statistical comparisons are made between the following groups: control group 2 and the region with inflammatory lesions in the treatment group, region and region inflammatory non-inflammatory group of medications and treatment before inflammatory region before and after treatment.
Serological blood measurements [6 months]
Comparison of serological blood measurements of free and total testosterone, dihydroepiandrosterone sulfate (DHEAS), luteinizing hormone (LH), follicle-stimulating hormone (FSH), and androsterone glucuronide, before and after the treatment.

Eligibility Criteria

Criteria

Ages Eligible for Study:

26 Years to 44 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

To all:

Signing the consent form before any study procedures;
women aged 26 to 44 years, not pregnant and in good health;
no topical treatment for acne in the past three months,
absence of the use of oral antibiotics in the last 3 months;
absence of the use of isotretinoin in the last 2 years;
absence of oral contraceptive use in the last 3 months;
absence of clinical evidence of immunosuppression and
accordance with the conditions of study, ability to understand and strictly follow the instructions given.

For the oral contraceptives group:

No contraindications to the use hormonal contraceptives.

For the azelaic acid group:

Absence of hypersensitivity to azelaic acid.

Exclusion Criteria:

For all

Women who do not agree with the conditions of the study or without the ability to understand and closely follow the guidelines received without availability to attend the revaluations or who refuse to sign the Informed Consent Form;
pregnant or lactating women;
use of the following oral medications: cortisone derivatives, lithium, anticonvulsants, isoniazid, oral contraceptives, androgens, danazol, iodides, bromides, disulfiram, cyclosporine, azathioprine, thiuram, vitamins B2, B6 and B12;
treatment of facial skin with topical retinoids (tretinoin and adapalene), azelaic acid, benzoyl peroxide, clindamycin, erythromycin, nicotinamina, alone or in combination, in the past 3 months;
treatment with oral antibiotics in the past 3 months;
acnogenics cosmetics.

For the group treated with oral contraceptives:

Presence of contraindications to oral contraceptive use:
Smokers over 35 years;
history of deep venous thrombosis;
history of stroke;
history of breast cancer;
presence of jaundice, and severe active liver disease or biliary disease;
diabetes mellitus for more than 20 years or eye injury, or neurological impairment;
blood pressure greater than or equal to 160 to 100 for systolic and diastolic;
cardiovascular disease and
presence of severe headache associated with blurred vision frequently.